Reported Earlier, Corbus Pharmaceuticals Proposes To Offer And Sell Common Shares In An Underwritten Registered Public Offering
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals announced its intention to offer and sell shares of its common stock or pre-funded warrants in an underwritten registered public offering. The offering's completion, size, and terms are subject to market conditions. Proceeds will fund clinical development and provide working capital and general corporate purposes.
January 31, 2024 | 5:55 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Corbus Pharmaceuticals is conducting a public offering of common stock or pre-funded warrants to raise funds for clinical development and other corporate expenses.
Public offerings often lead to dilution of existing shares, which can result in a short-term negative impact on the stock price. The uncertainty around the offering's terms and size also adds to market apprehension.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100